MedTrace Logo

EPI-743 for Mitochondrial Respiratory Chain Diseases

NCT01370447 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-01-23

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.

Conditions

  • Mitochondrial Diseases

Interventions

DRUG

EPI-743

EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.

Sponsors & Collaborators

Principal Investigators

  • Gregory Enns, MB, ChB · Stanford University

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01370447 on ClinicalTrials.gov